- Stocks
- Pharma & Healthcare
- Shree Ganesh Re
Shree Ganesh Re share price
NSE: SGRLPharma & HealthcareDrug Manufacturers - Specialty & Generic
Shree Ganesh Re at a glance
Shree Ganesh Re (NSE: SGRL) closed at ₹658.25 on 22 Oct 2026, up 3.32% on the day. With a market capitalisation of ₹845 Cr, it ranks 1546th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 47.7× trailing earnings, against a return on equity of 10.9% in FY26. Its 52-week range is ₹477.05 (17 Aug 2026) to ₹749.85 (23 Sep 2026); the last close is 12.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹33 Cr (+35.9% year on year) and net profit ₹6 Cr (−4.9%), on a consolidated basis. Promoters held 72.84% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹845 CrRank 1546 on NSE
- P/E (trailing)
- 47.7×
- Price to book
- 3.31×FY26
- EPS (TTM)
- ₹13.83to Q4 FY26
- ROE
- 10.9%FY26
- ROCE
- 14.8%FY26
- Debt to equity
- 0.19FY26
- Net profit margin
- 16.3%FY26
- Book value / share
- ₹126.95FY26
- 52-week high
- ₹749.8523 Sep 2026
- 52-week low
- ₹477.0517 Aug 2026
- RSI (14-day)
- 48
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +3.32% | −0.9% | −8.2% | — | — |
Shree Ganesh Re quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹25 Cr | ₹32 Cr | ₹27 Cr | ₹24 Cr | ₹25 Cr | ₹30 Cr | ₹21 Cr | ₹33 Cr |
| Revenue YoY | — | — | — | −34.6% | −0.4% | −6.2% | −22.0% | +35.9% |
| Net profit | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹7 Cr | ₹3 Cr | ₹5 Cr | ₹3 Cr | ₹6 Cr |
| Net profit YoY | — | — | — | −47.6% | −25.8% | −22.6% | −43.0% | −4.9% |
| Net margin | 18.8% | 19.8% | 20.0% | 27.0% | 14.0% | 16.4% | 14.6% | 18.9% |
| EPS | ₹3.62 | ₹4.97 | ₹4.22 | ₹5.13 | ₹2.68 | ₹3.86 | ₹2.41 | ₹4.88 |
Shree Ganesh Re financials
| Item | FY19 | FY20 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹35 Cr | ₹64 Cr | ₹126 Cr | ₹109 Cr | — |
| Operating profit | ₹9 Cr | ₹14 Cr | ₹38 Cr | ₹31 Cr | — |
| Net profit | ₹6 Cr | ₹10 Cr | ₹28 Cr | ₹23 Cr | — |
| EPS (₹) | ₹7.00 | ₹12.00 | ₹22.00 | ₹18.00 | — |
| Cash from operations | −₹5 Cr | ₹5 Cr | ₹30 Cr | ₹31 Cr | — |
| Total debt | ₹0 Cr | ₹2 Cr | ₹29 Cr | ₹29 Cr | ₹21 Cr |
| Shareholders' equity | ₹34 Cr | ₹42 Cr | ₹122 Cr | ₹145 Cr | ₹163 Cr |
Shree Ganesh Re shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.80% | 72.80% | 72.80% | 72.80% | 72.84% | 72.84% |
| Domestic institutions | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.52% |
| Non-institutions | 27.19% | 27.19% | 27.19% | 27.20% | 27.16% | 26.64% |
Shree Ganesh Re vs peers
The listed Pharma & Healthcare companies nearest to Shree Ganesh Re by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| THEMISMEDThemis Medicare | ₹98.08 | +3.13% | −22.8% | ₹903 Cr | — | — |
| SGRLShree Ganesh Re | ₹658.25 | +3.32% | — | ₹845 Cr | 47.7 | — |
| ANUHPHRAnuh Pharma | ₹80.29 | +0.68% | +0.4% | ₹805 Cr | 19.6 | — |
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
Ask anything about Shree Ganesh Re
Pivot answers on the live chart with evidence you can check, and tests strategies against SGRL's own history. Try: “Why has SGRL moved over the last three months?” · “Backtest a 50-day moving-average crossover on SGRL over five years” · “Compare SGRL with THEMISMED on margins and valuation”
Frequently asked questions about Shree Ganesh Re
What is the share price of Shree Ganesh Re today?
Shree Ganesh Re (NSE: SGRL) last closed at ₹658.25 on 22 Oct 2026. Its 52-week high is ₹749.85 and its 52-week low is ₹477.05.
What is the market cap of Shree Ganesh Re?
Shree Ganesh Re's market capitalisation is ₹845 Cr (₹845 Cr) at the 22 Oct 2026 close, ranking 1546th among the NSE companies Pivot tracks.
What is the P/E ratio of Shree Ganesh Re?
Shree Ganesh Re trades at a trailing P/E of 47.7. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 24.2.
What is the ROE and ROCE of Shree Ganesh Re?
Return on equity was 10.9% in FY26 and return on capital employed was 14.8% in FY26 (consolidated figures).
Is Shree Ganesh Re a debt-free company?
No. Shree Ganesh Re's debt-to-equity ratio was 0.19 in FY26, with total debt of ₹21 Cr.
What were Shree Ganesh Re's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Shree Ganesh Re reported revenue of ₹33 Cr, +35.9% year on year, and net profit of ₹6 Cr, −4.9% year on year.
What is the shareholding pattern of Shree Ganesh Re?
As of 30 Jun 2026: promoters 72.84%, domestic institutions 0.52%, non-institutions 26.64%.
Who are Shree Ganesh Re's competitors?
The listed Pharma & Healthcare companies closest to Shree Ganesh Re by market cap are Themis Medicare, Anuh Pharma, Kilitch Drugs (India), Vikram Thermo, Zim Laboratories and Valiant Laboratories.
Is Shree Ganesh Re a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Shree Ganesh Re's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SGRL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text